Brief: Anixa Biosciences And MolGenie Announce Early Potency Analysis Of SARS-CoV-2 Protease Inhibitor
24/01/2022 14:18
Jan 24 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES AND MOLGENIE ANNOUNCE EARLY POTENCY
ANALYSIS
OF SARS-COV-2 PROTEASE INHIBITOR
* ANIXA BIOSCIENCES INC - EXPECTS ITS COMPOUNDS WILL BE
EFFECTIVE
AGAINST ALL CURRENTLY KNOWN VARIANTS
Source text for Eikon: ID:nPn5FjpDga
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine